Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin ...

- Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic ...

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and ...

It was a decade and four companies ago that HyQvia was first approved by the FDA for primary immunodeficiency (PI). Ten years later, Takeda’s subcutaneous immune globulin treatment has scored its ...

Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 ...

In patients with inborn errors of immunity who are prone to viral infections, immunoglobulin replacement therapy (IRT) administered via the conventional subcutaneous route showed lower viral infection ...

Intravenous immunoglobulin (IVIg) is a treatment that can boost antibody levels in people with immunodeficiencies, autoimmune diseases, or inflammatory conditions. It contains antibodies, which are ...

(MENAFN- GlobeNewsWire - Nasdaq) The global immunoglobulin market is set to grow at a 6.7% CAGR from 2025 to 2033, driven by rising autoimmune disorders and immunodeficiencies. Innovations in plasma ...